奥马佐单抗
慢性荨麻疹
医学
药品
内科学
皮肤病科
药理学
免疫学
免疫球蛋白E
抗体
作者
Murat Türk,Emek Kocatürk,Kübra Cüre,İnsu Yılmaz
标识
DOI:10.1016/j.jaip.2018.01.027
摘要
The effectiveness of omalizumab in chronic spontaneous urticaria (CSU) and symptomatic dermographism has been demonstrated in many clinical and real-life studies.1,2 A wide range of dosage from 75 mg to 600 mg was applied in these efficiency studies, and it was proved that the drug efficiency was dose dependent and most efficient dosage in CSU is 300 mg/4 wk.1 However, there are also data that suggest increasing the dose or shortening the intervals particularly when the symptoms cannot be controlled,3 but there is still no consensus on this subject.
科研通智能强力驱动
Strongly Powered by AbleSci AI